TCGX Closes $1.3B Fund III, Totaling $3.1B Since 2021

INVL Private Equity Fund II, the largest private equity fund in the Baltics, managed by the Invalda INVL Group, together with the IFC - International Finance Corporation (IFC), a member of the World Bank Group, and Accession Capital Partners (ACP) have signed an agreement to invest in POLMED S.A. POLMED is one of Poland’s largest private providers of multi-profile medical services. The consortium will provide expansion capital to finance the acquisition of KN Group, a leading privately-owned oncology centre. Upon completion, this will mark one of the first two acquisitions by the INVL Private Equity Fund II. Luke Staniczek, Investments Lead in Poland at INVL Private Equity Fund II, noted: “Our journey with InMedica proved that with the right support, a healthcare provider can grow into a national leader and deliver outstanding results for everyone – shareholders, patients and healthcare ecosystem as a whole. We are confident that POLMED, its founders and their team all have the same potential in Poland, and we look forward to supporting their growth and building our success story together.” Read more: https://lnkd.in/d6W2QrFE #invaldainvl #privateequity #fund #agreement #investment #medical #acquisition #POLMED

According to one study, autoimmune diseases cumulatively affect 5 to 10% of the industrial world population (1) (2). In the United States, the prevalence is estimated to be around 8%, or roughly 27 million people. Prevalence at these levels will need increasing rates of breakthrough medicines. So glad to see the VC investment from Arthritis National Research Foundation and the founding of Immune Boost Capital . #autoimmune #biotech #innovativemedicine

Today, the Arthritis National Research Foundation (ANRF) announced the launch of Immune Boost Capital (IBC), a wholly owned 501(c)(3) subsidiary designed to fill a critical funding gap between academic discovery and commercial development in autoimmune disease. IBC is a philanthropic evergreen venture fund that will provide proof-of-concept funding for early-stage biotech companies and academic spinouts. Unlike traditional venture funds, 100% of returns will be reinvested to fuel future opportunities. Importantly, this initiative does not replace ANRF’s long-standing mission of funding innovative early-career investigators—it complements it, ensuring more promising science has the chance to advance into therapies for patients. This initiative has the potential to accelerate the development of transformative treatments for autoimmune disease. 👉 Read the full press release here: https://lnkd.in/gkuc3WQi 🌐 Learn more at: www.immuneboostcapital.org #AutoimmuneDisease #VenturePhilanthropy #BiotechInnovation #ANRF #ImmuneBoostCapital #AutoimmuneInnovation

Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund -- Existing and new investors joining forces to support the accelerated development of Omnix´s novel, first-in-class antimicrobials pipeline -- Funding underlines urgent global need for novel, resistance-proof antimicrobials Congrats, great milestone for advancing Omnix´ leading-edge antimicrobials pipeline, Moshik Cohen-Kutner Niv Bachnoff and team! https://lnkd.in/er49Umc7 #amr #antibiotics #antimicrobials #financing #funding #antimicrobialresistance #antibioticresistance

Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund -- Existing and new investors joining forces to support the accelerated development of Omnix´s novel, first-in-class antimicrobials pipeline -- Funding underlines urgent global need for novel, resistance-proof antimicrobials Congrats, great milestone for advancing Omnix´ leading-edge antimicrobials pipeline, Moshik Cohen-Kutner Niv Bachnoff and team! https://lnkd.in/er49Umc7 #amr #antibiotics #antimicrobials #financing #funding #antimicrobialresistance #antibioticresistance

We are pleased to announce the closing of our $60.3 million oversubscribed raise. These funds will support advancement of our RT-114 program in obesity and further advance our RaniPill® platform. The private placement was led by a new investor Samsara BioCapital and included a combination of other new and existing stakeholders, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mir Imran, Founder and Executive Chairman of Rani. Read more here: https://lnkd.in/gkaaRpyE

POLMED: Investment Raised From Consortium: INVL Private Equity Fund II, known as one of the largest private equity funds in the Baltic region and managed by the Invalda INVL Group, has officially entered into an investment agreement with POLMED. This strategic partnership also includes the International Finance Corporation (IFC), a member of the World Bank Group, and Accession Capital Partners (ACP). POLMED stands out as one of the largest private providers of multi-profile medical services in Poland, with a significant presence in the healthcare sector. The post POLMED: Investment Raised From Consortium appeared first on Pulse 2.0.

🌐 Stifel is pleased to have acted as Sole Financial Advisor to a consortium led by Naxicap Partners on the sale of MEDIPREMA group, a leading European provider of neonatal care solutions, to private equity investors InnovaFonds and Sodero. 🏥 Médipréma Group combines the expertise of Médipréma and Beldico to design, manufacture, and distribute specialised equipment and consumables for Neonatal Intensive Care Units (NICUs). With 200+ employees and a presence in over 50 countries, the Group has established itself as a European leader in neonatal care. 🩺 This partnership with InnovaFonds and Sodero will support the Group’s strategic ambitions by accelerating international growth, driving innovation across its product portfolio, and enabling targeted acquisitions to strengthen its leadership in neonatal care. Laurent COLLEATTE, Laure Marchais, Xavier GELOT, Ronan AUFFRET, Cyriaque Viaud, Cyril Chaumien, Ophelie Gasselin

Blackstone veteran Tony James launches biotech fund through family office. The New York-based fund will target innovative medical businesses from early-stage development through to commercialisation. It will be led by biotech entrepreneur Laura Lande-Diner as Managing Partner and supported by a team of more than six senior advisers. Jefferson Life Sciences expands on James’ existing healthcare portfolio, which includes investments in PM Pediatric Care, a US-based provider of children’s medical services, and Renalytix, a London-listed company developing AI-enabled solutions for kidney disease. See how Tony James’ new biotech fund is reshaping his post-Blackstone legacy: https://lnkd.in/dYCnYsBe #PEInsights #privateequity #fundraising #biotech

Oh, what a week INVL Private Equity Fund II (the largest in the Baltics) has signed not one, but two major deals. Following the agreement I wrote about earlier this week to acquire Eesti Keskkonnateenused in Estonia, the fund, together with IFC - International Finance Corporation (World Bank Group) and Accession Capital Partners, has also invested in POLMED S.A., one of Poland’s largest private healthcare providers. The consortium will support POLMED’s growth with the acquisition of KN Group, a leading oncology centre. 👏👏👏 team - Nerijus Drobavičius, Luke Staniczek, and Marius Lepeška For our INVL Šeimos biuras Family Office investors, this is proof of consistency. We keep building in sectors that matter: sustainability, healthcare, (more to come). And we keep delivering opportunities that align with long-term value creation. Two deals announced in one week!